RT Book, Section
A1 Lee, Hans C.
A1 Patel, Krina
A1 Kongtim, Piyanuch
A1 Parmar, Simrit
A1 Lin, Pei
A1 Qazilbash, Muzaffar H.
A1 Thomas, Sheeba
A1 Manasanch, Elisabet E.
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
SR Print(0)
ID 1126741074
T1 Multiple Myeloma and Other Plasma Cell Dyscrasias
T2 The MD Anderson Manual of Medical Oncology, 3e
YR 2016
FD 2016
PB McGraw-Hill Medical
PP New York, NY
SN 9780071847940
LK hemonc.mhmedical.com/content.aspx?aid=1126741074
RD 2024/04/23
AB Plasma  cell  dyscrasias  are  heterogeneous  disorders  arising  from  the  proliferation  of  a  monoclonal  population  of  plasma  cells.  Some  of  these  disorders  can  present  serendipitously  as  benign  processes  that  can  be  observed;  others  are  highly  aggressive  and  require  immediate  intervention.  The  most  common  plasma  cell  dyscrasia  is  monoclonal  gammopathy  of  undetermined  significance  (MGUS),  a  benign  condition  that  can  be  observed.  Related  disorders  include  smoldering  multiple  myeloma  (SMM),  multiple  myeloma  (MM),  solitary  plasmacytoma  of  the  bone,  extramedullary  plasmacytoma,  Waldenström  macroglobulinemia  (WM),  primary  amyloid  light-chain  (AL)  amyloidosis,  heavy-chain  disease,  POEMS  (polyneuropathy,  organomegaly,  endocrinopathy,  monoclonal  gammopathy,  and  skin  changes)  syndrome,  and  the  recently  recognized  TEMPI  (telangiectasias,  elevated  erythropoietin  and  erythrocytosis,  monoclonal  gammopathy,  perinephric  fluid  collection,  and  intrapulmonary  shunting)  syndrome.  The  spectrum  of  MGUS,  SMM,  and  MM  represents  a  natural  progression  of  the  same  disease.  This  chapter  focuses  on  the  etiology,  genetics,  biology,  diagnosis,  clinical  features,  and  current  therapy  of  MM  and  other  plasma  cell  disorders.